Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 91

Sort by

Sort Order Select

Journal Articles

Single-cell analysis of the multiple myeloma microenvironment after gamma-secretase inhibition and CAR T-cell therapy

David G Coffey, Pinar Ataca Atilla, Erden Atilla, Ola Landgren, Andrew J Cowan, Sylvain Simon, Margot Pont, Melissa L. Comstock, Geoffrey R Hill, Stanley R. Riddell, Damian J Green

Blood blood.2024025231.

https://doi.org/10.1182/blood.2024025231

Published: 2024

Includes: Supplemental data

Journal Articles

Human herpesvirus 6 reactivation and disease are infrequent in chimeric antigen receptor T-cell therapy recipients

Eleftheria Kampouri, Elizabeth M. Krantz, Hu Xie, Sarah S. Ibrahimi, Erika S. Kiem, Mandeep K. Sekhon, Emily C. Liang, Andrew J. Cowan, Andrew Portuguese, Damian J. Green, Aya Albittar, Jennifer J. Huang, Jordan Gauthier, Ailyn C. Pérez-Osorio, Keith R. Jerome, Danielle M. Zerr, Michael J. Boeckh, Joshua A. Hill

Blood (2024) 144 (5): 490–495.

https://doi.org/10.1182/blood.2024024145

Published: 2024

Includes: Supplemental data

Journal Articles

Regulatory T cells suppress myeloma-specific immunity during autologous stem cell mobilization and transplantation

Shuichiro Takahashi, Simone A. Minnie, Kathleen S. Ensbey, Christine R. Schmidt, Tomoko Sekiguchi, Samuel R. W. Legg, Ping Zhang, Motoko Koyama, Stuart D. Olver, Alika D. Collinge, Sara Keshmiri, Melissa L. Comstock, Antiopi Varelias, Damian J. Green, Geoffrey R. Hill

Blood (2024) 143 (16): 1656–1669.

https://doi.org/10.1182/blood.2023022000

Published: 2024

Includes: Supplemental data

Journal Articles

Resistance to CD38 Antigen Targeted Therapy in Multiple Myeloma May Result from Underrecognized Chromosome 4 Gene Deletions

Andrew J Portuguese, Min Fang, Sherilyn A. Tuazon, Margot Pont, Xiaoyu Qu, Carolyn Shasha, Melissa L Comstock, Justina Lyons, Gabriel Cole, Evan W. Newell, Emily Glynn, Lorinda Soma, Damian J Green

Blood (2023) 142 (Supplement 1): 1976.

https://doi.org/10.1182/blood-2023-186688

Published: 2023

Journal Articles

Trogocytosis May Attenuate the Efficacy of Anti-BCMA CAR T Cells Administered in Combination with γ-Secretase Inhibitor

Pinar Ataca Atilla, Sylvain Simon, Erden Atilla, Melissa L Comstock, Andrew J. Cowan, Geoffrey R Hill, Stanley R. Riddell, Damian J Green

Blood (2023) 142 (Supplement 1): 2083.

https://doi.org/10.1182/blood-2023-187132

Published: 2023

Journal Articles

Impact of Gamma-Secretase Inhibition on the Multiple Myeloma Immune Microenvironment

David Coffey, Ola Landgren, Andrew J. Cowan, Pinar Ataca Atilla, Sylvain Simon, Margot Pont, Melissa L Comstock, Geoffrey R Hill, Stanley R. Riddell, Damian J Green

Blood (2023) 142 (Supplement 1): 4683.

https://doi.org/10.1182/blood-2023-186980

Published: 2023

Journal Articles

A Phase 2 Study of Nivolumab for Relapsed/Refractory Multiple Myeloma or Non-Hodgkin Lymphoma Following CAR-T Therapy

Blood (2023) 142 (Supplement 1): 3509.

https://doi.org/10.1182/blood-2023-173202

Published: 2023

Journal Articles

Machine Learning-Based Time-Series Clustering Identifies Archetypal Trajectories of Hematotoxicity after CAR T-Cell Therapy

Blood (2023) 142 (Supplement 1): 2143.

https://doi.org/10.1182/blood-2023-174106

Published: 2023

Journal Articles

BCMA-Directed Low Dose Alpha-Emitter Therapy Eliminates Minimal Residual Disease in a Multiple Myeloma Mouse Xenograft Model

Melissa L Comstock, Shyril O'Steen, Yukang Lin, Donald Hamlin, D Scott Wilbur, Johnnie J. Orozco, Rainer F. Storb, Roland B. Walter, Pinar Ataca Atilla, Brian G Till, Geoffrey R Hill, Brenda M. Sandmaier, Damian J Green

Blood (2023) 142 (Supplement 1): 53.

https://doi.org/10.1182/blood-2023-188055

Published: 2023

Journal Articles

Sea-BCMA Mono- and Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study (SGNBCMA-001)

James E. Hoffman, Brea Lipe, Jason Melear, Michaela Liedtke, Mark A. Schroeder, Ruben Niesvizky, Christopher Strouse, Christopher A. Yasenchak, Damian J. Green, Jeremy Sauer, Yinghui Wang, Phoenix Ho, Al-Ola Abdallah

Blood (2022) 140 (Supplement 1): 10160–10162.

https://doi.org/10.1182/blood-2022-157347

Published: 2022

Journal Articles

Plasma Cell Leukemia: A Multicenter Retrospective Study of 130 Patients

Iloabueke Chineke, Betsy Wertheim, Denise Roe, Ashley Larsen, Victoria A. Vardell, Douglas W. Sborov, Damian J. Green, Michaela Liedtke, Marie Okoniewski, Mohammed Wazir, Omar Nadeem, Levanto Schachter, David Coffey, Krisstina L. Gowin, Dominique DeGraaff

Blood (2022) 140 (Supplement 1): 7144–7146.

https://doi.org/10.1182/blood-2022-164713

Published: 2022

Journal Articles

Alternating the Administration of Ixazomib and Lenalidomide As Maintenance Therapy after Autologous Transplant for Multiple Myeloma

Leona A Holmberg, Damian J. Green, Sarah S Lee, Andrew J Cowan

Blood (2022) 140 (Supplement 1): 10575–10576.

https://doi.org/10.1182/blood-2022-160265

Published: 2022

Journal Articles

Long-term Follow-up of CD20-directed Chimeric Antigen Receptor Adoptive T-cell Therapy

George Mo, Sang Yun Lee, David G. Coffey, Valentin Voillet, IIan Kirsch, Damian J. Green, Raphael Gottardo, David G. Maloney, Oliver W. Press, Brian G. Till

Blood (2022) 140 (Supplement 1): 7460–7461.

https://doi.org/10.1182/blood-2022-159664

Published: 2022

Journal Articles

Timing of PD-L1 Blockade with Durvalumab May Affect Outcomes of CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Alexandre Vinaud Hirayama, Salvatore Fiorenza, Jordan Gauthier, Jenna M. Voutsinas, Qian Vicky Wu, Erik L. Kimble, Barbara S. Pender, Delaney R. Kirchmeier, Henna A. Di, Ryan D. Cassaday, Aude G. Chapuis, Damian J. Green, Hans-Peter Kiem, Filippo Milano, Mazyar Shadman, Brian G. Till, Stanley R. Riddell, David G. Maloney, Cameron J. Turtle

Blood (2022) 140 (Supplement 1): 7447–7449.

https://doi.org/10.1182/blood-2022-168185

Published: 2022

Journal Articles

Regulatory T Cell Depletion during Stem Cell Mobilization Enhances Anti-Myeloma Immunity after Experimental Autologous Stem Cell Transplantation

Shuichiro Takahashi, Simone A Minnie, Samuel RW Legg, Christine R Schmidt, Kathleen S Ensbey, Damian J. Green, Geoffrey R Hill

Blood (2022) 140 (Supplement 1): 2086–2087.

https://doi.org/10.1182/blood-2022-168117

Published: 2022

Journal Articles

KarMMa-7, a Phase 1/2, Dose-Finding and Dose-Expansion Study of Combination Therapies with Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)

Noopur S. Raje, Jesús G. Berdeja, Paula Rodriguez-Otero, Damian J. Green, Sundar Jagannath, Sagar Lonial, Adrianna Gipson, Andrea Caia, Nathan Martin, Zhihong Yang, Gianfranco Pittari, Maria-Victoria Mateos

Blood (2021) 138 (Supplement 1): 4830.

https://doi.org/10.1182/blood-2021-147412

Published: 2021

Journal Articles

Safety and Efficacy of Fully Human BCMA CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase BCMA Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma

Andrew J. Cowan, Margot Pont, Blythe Duke Sather, Cameron J. Turtle, Brian G. Till, Edward Libby, David G. Coffey, Sherilyn A. Tuazon, Brent L. Wood, Ted A Gooley, Qian Vicky Wu, Mazyar Shadman, Jordan Gauthier, Aude G. Chapuis, Filippo Milano, David G. Maloney, Stanley R. Riddell, Damian J. Green

Blood (2021) 138 (Supplement 1): 551.

https://doi.org/10.1182/blood-2021-154170

Published: 2021

Journal Articles

Safety and Efficacy of Two Anakinra Dose Regimens for Refractory CRS or Icans after CAR T-Cell Therapy

Blood (2021) 138 (Supplement 1): 2816.

https://doi.org/10.1182/blood-2021-147454

Published: 2021

Journal Articles

SEA-BCMA, an Investigational Nonfucosylated Monoclonal Antibody: Ongoing Results of a Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma (SGNBCMA-001)

James E Hoffman, Brea Lipe, Jason Melear, Michaela Liedtke, Mark A. Schroeder, Ruben Niesvizky, Michael H. Tomasson, Christopher A. Yasenchak, Damian J. Green, Hong Li, Yinghui Wang, Phoenix Ho, Al-Ola Abdallah

Blood (2021) 138 (Supplement 1): 2740.

https://doi.org/10.1182/blood-2021-146047

Published: 2021

Journal Articles

Safety and Efficacy of Third Generation CD20 Targeted CAR-T (MB-106) for Treatment of Relapsed/Refractory B-NHL and CLL

Blood (2021) 138 (Supplement 1): 3872.

https://doi.org/10.1182/blood-2021-149181

Published: 2021

NARROW

Single-cell analysis of the multiple myeloma microenvironment after gamma-secretase inhibition and CAR T-cell therapy

Human herpesvirus 6 reactivation and disease are infrequent in chimeric antigen receptor T-cell therapy recipients

Regulatory T cells suppress myeloma-specific immunity during autologous stem cell mobilization and transplantation

Resistance to CD38 Antigen Targeted Therapy in Multiple Myeloma May Result from Underrecognized Chromosome 4 Gene Deletions

Trogocytosis May Attenuate the Efficacy of Anti-BCMA CAR T Cells Administered in Combination with γ-Secretase Inhibitor

Impact of Gamma-Secretase Inhibition on the Multiple Myeloma Immune Microenvironment

A Phase 2 Study of Nivolumab for Relapsed/Refractory Multiple Myeloma or Non-Hodgkin Lymphoma Following CAR-T Therapy

Machine Learning-Based Time-Series Clustering Identifies Archetypal Trajectories of Hematotoxicity after CAR T-Cell Therapy

BCMA-Directed Low Dose Alpha-Emitter Therapy Eliminates Minimal Residual Disease in a Multiple Myeloma Mouse Xenograft Model

Sea-BCMA Mono- and Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study (SGNBCMA-001)

Plasma Cell Leukemia: A Multicenter Retrospective Study of 130 Patients

Alternating the Administration of Ixazomib and Lenalidomide As Maintenance Therapy after Autologous Transplant for Multiple Myeloma

Long-term Follow-up of CD20-directed Chimeric Antigen Receptor Adoptive T-cell Therapy

Timing of PD-L1 Blockade with Durvalumab May Affect Outcomes of CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Regulatory T Cell Depletion during Stem Cell Mobilization Enhances Anti-Myeloma Immunity after Experimental Autologous Stem Cell Transplantation

KarMMa-7, a Phase 1/2, Dose-Finding and Dose-Expansion Study of Combination Therapies with Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)

Safety and Efficacy of Fully Human BCMA CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase BCMA Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma

Safety and Efficacy of Two Anakinra Dose Regimens for Refractory CRS or Icans after CAR T-Cell Therapy

SEA-BCMA, an Investigational Nonfucosylated Monoclonal Antibody: Ongoing Results of a Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma (SGNBCMA-001)

Safety and Efficacy of Third Generation CD20 Targeted CAR-T (MB-106) for Treatment of Relapsed/Refractory B-NHL and CLL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only